| DC21070 |
GS-1 |
GS-1 is a close structural analog of GS-5806 that acts an RSV fusion inhibitor. |
|
| DC21068 |
GS-493 |
GS-493 is a novel potent, selective SHP2 inhibitor with IC50 of 71±15 nM in enzyme assay. |
|
| DC12579 |
GS-6207
Featured
|
GS-6207 (GS6207, GS-CA1) is a potent, selective inhibitor of HIV-1 capsid function with potency and potential to be clinically effective against a broad range of HIV-1 strains.. |
|
| DC23381 |
GS-626510 |
GS-626510 (GS-6510, GS 6510, GS 626510) is a novel BET family bromodomains inhibitor with Kd of 0.5-2.8 nM for BRD2/3/4, and BRDT. |
|
| DC7805 |
CID 121433863
Featured
|
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate. |
|
| DC9294 |
Tenofovir Alafenamide Hemifumarate
Featured
|
GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate. |
|
| DC21071 |
GS-9451 |
GS-9451 (Vedroprevir) is a potent HCV NS3/4A protease inhibitor with Ki of 0.41 nM, inhibits HCV GT-1b NS3/4A with IC50 of 3.2 nM in enzymatic assays. |
|
| DC7138 |
GS-9620(Vesatolimod)
Featured
|
GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7(TLR-7) in chimpanzees with chronic HBV infection. |
|
| DC8006 |
GS967(GS-458967)
Featured
|
GS967 is a novel, potent, and selective inhibitor of cardiac late sodium current(late INa). |
|
| DC23244 |
GS-9695 |
GS-9695 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 1.2 nM.. |
|
| DC11297 |
GS-9822 |
GS-9822 is a novel, potent NCINI with a higher barrier to resistance relative to early prototype NCINIs, including GS-9695. |
|
| DC7626 |
GS9973（Entospletinib）
Featured
|
GS-9973 is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM. Phase 2. |
|
| DC23876 |
GSA-10
Featured
|
GSA-10 is a novel small-molecule positive modulator of Smoothened with EC50 of 1.2 uM in the differentiation assay. |
|
| DC5147 |
Molibresib (I-BET-762)
Featured
|
GSK 525762A is a potent small molecule inhibitors that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4). |
|
| DC8360 |
GSK 5959
Featured
|
GSK 5959 is a potent, cell-permeable inhibitor of the BRPF1 bromodomain (IC50 = 80 nM). |
|
| DC7654 |
GSK J4 HCl
Featured
|
GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. |
|
| DC1036 |
GSK-0660
Featured
|
GSK-0660 is a selective PPARδ antagonist (IC50 values are 0.155, > 10 and ≥ 10 μM at PPARδ, PPARα and PPARγ respectively). |
|
| DC11280 |
GSK1016790A
Featured
|
GSK1016790A is a novel and potent TRPV4 channel agonist. |
|
| DC9515 |
PI3K inhibitor GS1059615 |
GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.
|
|
| DC7140 |
GSK1070916
Featured
|
GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM; displays >100-fold selectivity against the closely related Aurora A-TPX2 complex(IC50=490 nM). |
|
| DC7042 |
GSK-126
Featured
|
GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase with Ki value of 0.5 nM. |
|
| DC7422 |
GSK1292263
Featured
|
GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. |
|
| DC8766 |
GSK1324726A (I-BET726)
Featured
|
GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), and BRD4 (IC50= 22 nM). |
|
| DC8577 |
FFA4 (GPR120) agonist GSK137647A
Featured
|
GSK-137647 is a potent and selective FFA4 (GPR120) agonist (pEC50 values are 6.3, 6.2 and 6.1 at the human, mouse and rat receptor, respectively). Exhibits ≥100-fold selectivity against a panel of 61 targets including FFA1, FFA2 and FFA3. |
|
| DC9705 |
GSK163090
Featured
|
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively. |
|
| DC10124 |
GSK180736A
Featured
|
GSK180736A is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM. |
|
| DC10102 |
GSK189254A
Featured
|
GSK189254A (GSK189254) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively. |
|
| DC2069 |
IGF-1R inhibitor GS1904529A |
GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, respectively. |
|
| DC9714 |
SCD inhibitor GSK1940029
Featured
|
GSK1940029 is a stearoyl CoA desaturase 1 inhibitor. |
|
| DC20282 |
GSK199
Featured
|
GSK199 is a reversible inhibitor of PAD4 (IC50 = 200 nM) that binds to the low-calcium form of the enzyme and is selective for PAD4 over PAD1-3. |
|
